Session Chairs
1st Kuwait Familial Hypercholesterolemia Symposium & 4th Severe FH Masterclass - Day 2
Pre-activity information
The 1st Kuwait Familial Hypercholesterolemia Symposium and the 4th IAS Severe FH Master Class is targeted to meet the educational needs of medical professionals in clinical practice engaged in the prevention or the management of patients demonstrating risk or with established cardiovascular disease.
By participating in these educational offerings, the learner is expected to be able to:
1) Recognize, diagnose, and treat severe familial hypercholesterolemia (both HeFH and HoFH) in accordance with current guidelines.
2) Discuss the implications of family history, consanguinity, and cascade screening.
3) Discuss the complications of familial hypercholesterolemia.
4) Discuss HoFH and pregnancy.
5) Discuss HoFH and COVID-19.
6) Outline the clinical indications of LDL apheresis.
7) Evaluate the efficacy, safety, and tolerability of various drugs for the treatment of severe familial hypercholesterolemia to implement appropriately targeted treatment plans.
8) Diagnosis and management of pediatric HeFH and HoFH.
9) Work collaboratievely to analyze and discuss several case studies.
The IAS is proud to present this esteemed global faculty. More information on each faculty member can be found by clicking on their name.
Khalid Al Rasadi, MD
Disclosures | Date of Disclosures |
Consultant or advisory board member from Astra Zeneca, Pfizer, Sanofi, Aegerion and Abbott. Grant and Research support received from Sanofi. | 19-02-2021 |
Marcello Arca, MD
Disclosures | Date of Disclosures |
Prof. Arca has received payments for the provision of: Grants and consulting services: Akcea/Ionis, Alfasigma, Amgen, Amryt, Daichi-Sankyo, Pfizer, Novartis, Regeneron, Sanofi; participation as a speaker at scientific meetings: Alfasigma, Amgen, Amryt, DAICHI-Sankyo, Regeneron, Sanofi | 19-02-2021 |
Khalid Al Waili, B.Sc., MD, FRCPC, DABCL
Disclosures | Date of Disclosures |
| 19-02-2021 |
Daniel Gaudet, MD, PhD
Disclosures | Date of Disclosures |
Dr. Gaudet is an employee of Universite de Montreal. He reports professionnal relationship with Aegerion (Amryt), Akcea, Amgen, Novartis, Regeneron (Honoraria/ Expenses, Consulting/ Advisory Board and Funded Research), Esperion, Gemphire (Funded Research), Eli Lilly and Verve (Honoraria/ Expenses, Consulting/ Advisory Board). | 19-02-2021 |
Nasreen Al-Sayed, BMedSc, MD, FACP, FACE
Disclosures | Date of Disclosures |
Lecturer: Abbott, AstraZeneca, Merck Sharp, Sanofi, Pfizer, Amgen. Advisory Board: Sanofi, Aegerion, Merck Sharp. | 19-02-2021 |
Zuhier Awan, MD, MSc, PhD, FRCPC, FACB, FNLA, FAHA, FACE
Disclosures | Date of Disclosures |
Honoraria: Sanofi, Amgen and Amryt | 19-02-2021 |
Tiziana Sampietro, MD, PhD
Disclosures | Date of Disclosures |
Honoraria for advisory boards: Daichi-Sankyo. Speaker fees: Sanofi, Amgen. Clinical trials -payment to institution: Amgen, Sanofi, Daichi-Sankyo Novartis. | 19-02-2021 |
Noor Al Rajhi, MD
There are no Disclosure Statements for Dr. Noor Al Rajhi
Khadijah AlElaj, MD
There are no Disclosure Statements for Dr. Khadijah AlElaj
Ahmad Al Sarraf, MD, FRCPC
There are no Disclosure Statements for Dr. Ahmad Al Sarraf
Staff Disclosures
Staff involved with the development of this activity have nothing to disclose.
The IAS is very grateful to Amryt Pharma, Amgen, Kaneka, Sanofi and AAW for supporting the 1st Kuwait Familial Hypercholesterolemia Symposium & 4th Severe FH Masterclass through an unrestricted educational grant. We also thank all the faculty and clinician attendees who shared their experience and contributed to the IAS in its global mission.